Evommune, Inc. (EVMN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US30054Y1073
Evommune, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 13.00 m USD |
| Operating income | -81.07 m USD |
| EBIT | -72.19 m USD |
| Net income | -68.87 m USD |
| Diluted EPS – continuing operations | -11.22 USD |
Full history since 2023, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
More stocks
- JSL S.A (JSLG3.SA)
- CION Investment Corp (CION)
- ASURE SOFTWARE INC (ASUR)
- VERRA MOBILITY Corp (VRRM)
- Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937.SZ)
- Capex S.A (CAPX.BA)
- Cabaletta Bio, Inc. (CABA)
- FRANKLIN FINANCIAL SERVICES CORP /PA/ (FRAF)
- Desiccant Technology Corporation (5292.TW)
- Daqing Huake Co Ltd (000985.SZ)
- cBrain A/S (CBRAIN.CO)
- CHT Security Co., Ltd. (7765.TW)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.